两性霉素 B 脂质复合物：治疗对两性霉素 B 去氧胆酸盐耐药或不耐受的侵袭性真菌感染患者。
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate.
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Wayne State University, Karmanos Cancer Institute, Detroit, MI, USA.
出版信息
Ther Clin Risk Manag. 2008 Dec;4(6):1285-94. doi: 10.2147/tcrm.s1554.
Abstract
Amphotericin B lipid complex (ABLC) was introduced in the late 1990s as a less toxic alternative to amphotericin B (AmB) deoxycholate. ABLC is a safe and effective broad-spectrum drug in the treatment of invasive fungal infections in patients with infection refractory to AmB deoxycholate or in patients intolerant of the same formulation. The drug has not been rigorously evaluated for primary therapy. Recent availability of several newer potent and safe drugs has sharply curtailed the use of potentially nephrotoxic ABLC. However, AmB lipid complex is likely to continue to play a limited albeit significant clinical role in view of the narrow spectrum of activity and significant drug-drug interactions of the newer drugs and emergence of drug-resistant fungi.
摘要
两性霉素 B 脂质复合物（ABLC）于 20 世纪 90 年代末作为两性霉素 B 去氧胆酸盐的毒性较低的替代品问世。ABLC 是一种安全有效的广谱药物，可用于治疗对两性霉素 B 去氧胆酸盐耐药或不能耐受该制剂的侵袭性真菌感染患者。该药物尚未经过严格评估用于一线治疗。最近几种新型强效且安全的药物的出现，极大地限制了潜在肾毒性 ABLC 的使用。然而，鉴于新型药物的作用谱狭窄且药物相互作用明显，以及耐药真菌的出现，两性霉素 B 脂质复合物可能仍将继续发挥有限但重要的临床作用。
相似文献
1
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate.两性霉素 B 脂质复合物：治疗对两性霉素 B 去氧胆酸盐耐药或不耐受的侵袭性真菌感染患者。
Ther Clin Risk Manag. 2008 Dec;4(6):1285-94. doi: 10.2147/tcrm.s1554.
2
Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.在美国，治疗侵袭性真菌感染中脂质体两性霉素 B 和两性霉素 B 脂质复合物的预算影响分析。
Appl Health Econ Health Policy. 2014 Feb;12(1):85-93. doi: 10.1007/s40258-013-0072-7.
3
Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature.两性霉素B脂质复合物（ABLC）的疗效、安全性及成本效益：文献综述
Curr Med Res Opin. 2004 Apr;20(4):485-504. doi: 10.1185/030079904125003179.
4
Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.脂质体两性霉素B：关于其在发热性中性粒细胞减少症经验性治疗及侵袭性真菌感染治疗中应用的综述
Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010.
5
A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.脂质体两性霉素B制剂肾毒性及疗效的前瞻性与回顾性分析
Pharmacotherapy. 2001 Sep;21(9):1107-14. doi: 10.1592/phco.21.13.1107.34613.
6
Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.脂质体两性霉素B与两性霉素B脂质复合物对血液系统恶性肿瘤合并侵袭性真菌感染患者肝脏组织病理学的影响：一项回顾性、非随机尸检研究
Clin Ther. 2007 Sep;29(9):1980-6. doi: 10.1016/j.clinthera.2007.09.016.
7
Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.两性霉素B脂质复合物、两性霉素B和氟康唑的体外抗真菌活性比较
Chemotherapy. 2000 Jul-Aug;46(4):235-44. doi: 10.1159/000007295.
8
In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?两性霉素B脂质复合物的体外和体内抗真菌活性：磷脂酶重要吗？
Antimicrob Agents Chemother. 1998 Apr;42(4):767-71. doi: 10.1128/AAC.42.4.767.
9
Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.两性霉素B脂质复合物与两性霉素B脂质体治疗真菌感染的药物经济学分析
Pharmacoeconomics. 2004;22(5):301-10. doi: 10.2165/00019053-200422050-00004.
10
[Multidisciplinary expert consensus on the clinical rational application of different formulations of amphotericin B (2024 edition)].两性霉素B不同剂型临床合理应用多学科专家共识（2024年版）
Zhonghua Nei Ke Za Zhi. 2024 Mar 1;63(3):230-257. doi: 10.3760/cma.j.cn112138-20231122-00332.
引用本文的文献
1
Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil.巴西念珠菌血症和其他形式侵袭性念珠菌病患者使用阿尼芬净治疗的成本效果分析和预算影响。
Rev Inst Med Trop Sao Paulo. 2023 Jan 30;65:e9. doi: 10.1590/S1678-9946202365009. eCollection 2023.
2
Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.多烯类和唑类药物治疗眼部真菌感染的挑战。
J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):6-22. doi: 10.1089/jop.2018.0089. Epub 2018 Nov 8.
3
A complex game of hide and seek: the search for new antifungals.一场复杂的捉迷藏游戏：寻找新型抗真菌药物
Medchemcomm. 2016 Jul 1;7(7):1285-1306. doi: 10.1039/C6MD00222F. Epub 2016 May 17.
4
Advances and Challenges of Liposome Assisted Drug Delivery.脂质体辅助药物递送的进展与挑战
Front Pharmacol. 2015 Dec 1;6:286. doi: 10.3389/fphar.2015.00286. eCollection 2015.
5
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.只需一种药物就能发挥多种作用：两性霉素B作为抗真菌和免疫调节药物。
Front Microbiol. 2012 Aug 8;3:286. doi: 10.3389/fmicb.2012.00286. eCollection 2012.
本文引用的文献
1
Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.两性霉素B脂质复合物与两性霉素B脂质体在急性侵袭性肺曲霉病小鼠模型中肺蓄积及真菌清除动力学的比较分析
Antimicrob Agents Chemother. 2007 Apr;51(4):1253-8. doi: 10.1128/AAC.01449-06. Epub 2007 Jan 29.
2
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.波氏假阿利什菌复合体各菌种的抗真菌药敏性
Antimicrob Agents Chemother. 2006 Dec;50(12):4211-3. doi: 10.1128/AAC.00981-06. Epub 2006 Oct 2.
3
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003).一家三级癌症中心血液系统恶性肿瘤患者的侵袭性真菌感染：一项为期15年（1989 - 2003年）的尸检研究
Haematologica. 2006 Jul;91(7):986-9. Epub 2006 Jun 1.
4
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.泊沙康唑作为接合菌病挽救治疗有效：91例回顾性总结
Clin Infect Dis. 2006 Apr 1;42(7):e61-5. doi: 10.1086/500212. Epub 2006 Feb 21.
5
Invasive candidiasis in the intensive care unit.重症监护病房中的侵袭性念珠菌病。
Crit Care Med. 2006 Mar;34(3):857-63. doi: 10.1097/01.CCM.0000201897.78123.44.
6
Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies.中剂量两性霉素B脂质复合物作为血液系统恶性肿瘤患者真菌感染的一线或挽救治疗的疗效及毒性
Leuk Lymphoma. 2005 Oct;46(10):1429-35. doi: 10.1080/10428190500205486.
7
Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).两性霉素B脂质复合体（ABLC）治疗异基因造血细胞移植（HCT）受者侵袭性曲霉病（IA）的疗效。
Bone Marrow Transplant. 2005 Nov;36(10):873-7. doi: 10.1038/sj.bmt.1705143.
8
Epidemiology and outcome of zygomycosis: a review of 929 reported cases.毛霉菌病的流行病学与转归：929例报告病例的综述
Clin Infect Dis. 2005 Sep 1;41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29.
9
Use of amphotericin B lipid complex in elderly patients.
J Infect. 2005 May;50(4):277-87. doi: 10.1016/j.jinf.2004.07.004.
10
Study of renal safety in amphotericin B lipid complex-treated patients.两性霉素B脂质复合物治疗患者的肾脏安全性研究。
Clin Infect Dis. 2005 May 1;40 Suppl 6:S414-21. doi: 10.1086/429335.
Zotero 插件